Arbutus Biopharma Corp (NAS:ABUS)
$ 3.34 -0.29 (-7.99%) Market Cap: 630.31 Mil Enterprise Value: 557.49 Mil PE Ratio: 0 PB Ratio: 5.22 GF Score: 60/100

Arbutus Biopharma Corp at JMP Securities Life Sciences Conference (Virtual) Transcript

Jun 15, 2022 / 01:00PM GMT
Release Date Price: $2.55 (+4.94%)
Roy Buchanan
JMP Securities LLC - Analyst

All right. Thank you, everyone, for joining us for the first day of the JMP Securities Life Sciences Conference. My name is Roy Buchanan, biotech analyst. And our first presenting company we have is Arbutus Biopharma. I have most of the team here -- Dave Hastings, CFO; Gaston Picchio, Chief Development Officer; and Mike Sofia, Chief Scientific Officer -- to tell us the story about Arbutus.

Questions & Answers

Roy Buchanan
JMP Securities LLC - Analyst

I'm actually going to start with Dave. So Dave, why don't you just remind us where cash was at the end of the last quarter, what you guided for runway, and how you're thinking about funding the next couple years as you ramp up the programs.

Dave Hastings
Arbutus Biopharma Corporation - CFO

Yeah. Thanks, Roy, and good morning, everybody. And Roy, thanks for hosting us today. We ended the first quarter of 2022 with $222 million in cash, which gives us about two years of runway into Q2 of 2024. So we've had significant

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot